What I Check Before I Sign Off on a Robotic Surgery System

I review surgical devices for a living. Not as an engineer, and not from behind a marketing slide. I check incoming systems and the documentation behind them—traceability reports, service plans, validation samples, the paperwork that most procurement teams never read. In 2024, I rejected about 11% of first-round submissions because the verification evidence didn't match the spec. The first thing I can tell you: the riskiest part of a robotic surgery system is rarely the robot.

Most buyers start with the obvious questions: Is the surgeon's console comfortable? Is the wrist articulation smooth? Can the system handle the case mix? I get it. I've sat through the same demo days. But after reviewing 200+ unique items a year, more often than not, the problem isn't the product in the demo suite. It's the system around the product.

The surface problem: you're evaluating the wrong 'system'

When someone says 'robotic surgery system,' they usually mean the surgical robot itself: a camera arm, two or three instrument arms, and a surgeon console. That's the visible 20 percent.

The other 80 percent is invisible until it fails: the maintenance plan, the sterile processing workflow for instruments, the software update path, the spare-parts warehouse, the clinical educator who trains your team, and the financial health of the company that has to keep all those promises.

That's the part nobody puts in the RFP. In my experience, that's where decisions get dangerous. So I want to walk through what I call the deep-risk side of due diligence. It doesn't replace the clinical evaluation. It protects it.

Deeper cause No. 1: We confuse visible product with invisible quality system

I have mixed feelings about the phrase 'quality system.' On one hand, it sounds like consultant-speak. On the other hand, it's the difference between a device that works in a demonstration and a device that works for five years.

Let me give you a strange example. I once asked my audit team a basic question before a cardiac instrument review: 'What is a heart valve?' You could hear the hesitation. People stammered about blood flowing one way, leaflets opening and closing. That's accurate, but it's not enough. A heart valve is a one-way gate that opens and closes around 100,000 times a day. The heart has four valves—mitral, tricuspid, aortic, and pulmonary—each made of leaflets. If a supplier can't explain the mechanics of something that basic, their entire quality file deserves closer inspection. FDA design-control requirements point the same direction: design inputs need to link to verification evidence. If that link is weak, the file will show it.

The same logic applies to a robotic surgery system. If the evaluation team can only describe the robot as 'a cool set of mechanical arms,' then you're not ready to evaluate the system. You're ready to be impressed by it.

Once you get past the console, real quality questions emerge: What happens if the system loses calibration mid-case? How many instrument uses are allowed? What is the reprocessing protocol? How is the 3D camera white-balanced and checked? These aren't trivia. They are checks that prevent a complication. And they don't show up on a demo.

Deeper cause No. 2: Financial health is treated as finance trivia

This one still surprises me. A hospital will spend four weeks comparing the angle of an instrument wrist but maybe thirty minutes on the vendor's ability to support the platform for the next decade. I used to do the same. I don't anymore.

In our Q1 2024 quality audit, I sat with the finance team and went through the public filings of every capital equipment vendor we were evaluating. We looked at two numbers in particular: return on invested capital (ROIC) and the debt-to-equity ratio.

ROIC matters because it tells you whether the company is investing in the product line or just milking it. The Intuitive Surgical ROIC 2024 figure was part of my review—not because a high ROIC makes a robot better, but because it tells you whether the company can keep funding service, training, software, and research. If ROIC is falling year after year, eventually the support team shrinks, software updates get delayed, and spare parts get more expensive.

The debt-to-equity ratio matters for the same reason. I'm not a 'debt is evil' person. But when a company is highly leveraged, every business distraction becomes your problem. Robotic surgery systems are not like smartphones; you can't replace them in two years. You're in a 7-to-10-year relationship. It's reasonable to ask whether your partner can make it that long.

I also search the 10-K for risk factors. I don't read all of it; I search for 'service,' 'recall,' 'supply chain,' and 'training.' If those words appear in the risk section, I read the surrounding paragraphs closely. That tells me what the company itself worries about.

Deeper cause No. 3: The accessories and consumables are the real system

This is where my colleagues in the lab world have been ahead of us for years. When I review a chemistry analyzer, I don't spend the morning watching it run samples. I ask about calibration reagents, carryover rates, maintenance cycles, and what the operator does when the results look wrong. The analyzer itself is a shell; the chemistry is the product.

Surgical robotics is the same. The robotic surgery system is a vessel. The instruments, the endoscopes, the accessories, the sterile drapes, the service contract, the training program—that's the product. And those are the budget lines where the math can quietly fall apart.

Here's a realistic calculation: the capital cost of the system is one number. But the annual spend on instruments and accessories can add 20-40 percent of the capital cost if you're running cases regularly. That's not a one-time purchase decision. It's an operating cost decision. If the evaluation only compares the robot price, it's incomplete. (Note to self: I need to put that exact percentage into every checklist I write.)

The price of skipping this: rework, idle capacity, and lost trust

Suppose you pick a system because the wrist has the most degrees of freedom. You skip the service-response review. Six months later, the system needs a maintenance visit. The vendor's first available slot is in 72 hours. Your surgical schedule collapses. The surgeons say, 'I told you this wasn't reliable.' The robot goes dark. That's not a technology failure. It's a due-diligence failure.

I still kick myself for an earlier decision in my career. I accepted a vendor's verbal promise that the service engineer was 'local.' It turned out he covered four states. If I'd validated the response time in writing—the service region and the callback SLA—we would have caught it before the contract. Instead, we spent a $22,000 rework and three weeks of schedule chaos. Five minutes of verification beats five days of correction.

The less obvious cost is trust. Every time a system goes down, surgeons lose confidence. They start booking cases on a different platform. The expensive robot becomes a backup. The facility sinks a million dollars into a machine that nobody schedules. That outcome has nothing to do with clinical superiority and everything to do with prevention.

The approach that protects the investment

If I sound like a checklist evangelist, I'm okay with that. The list is shorter than you might think.

1. Demand a lifecycle map. Installation, training, instrument inventory, reprocessing, software updates, service response, end-of-life. If any link is missing or vague, the whole chain is at risk.
2. Screen the financials. Look at ROIC and debt-to-equity ratio over three years. Read the 10-K risk factors. You don't need to become an analyst; you need to know whether the vendor can keep its promises.
3. Ask the 'what is a heart valve?' question. Ask each vendor to explain the core mechanism of their own device in simple terms. If they simplify too much, or can't answer, ask for the full technical file.
4. Put acceptance criteria into the contract. Uptime percentage, response time, training plan, spare part availability, software upgrade obligations. If it's not written down, it doesn't exist.
5. Inspect the consumables supply chain. For a robotic surgery system, the instruments and accessories are the real lifeblood. Verify they're available, validated, and priced predictably.

In the end, the best robotic surgery system is not necessarily the one with the most features. It's the one your hospital can actually support through the full lifecycle. It's the one where the financial model is sound, the quality system is deep, and the service plan is real. You can't see any of that in a demo. You can only see it if you check.

So check first. It's the least expensive step in the whole process.